Halozyme Therapeutics, Inc.
HALO
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other tā¦ read more
Healthcare
Biotechnology
21 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$68.24
Price-0.22%
-$0.15
1Y
Price
Market Cap
$8.025b
Mid
Price/Earnings 3y Avg5y Avg
14.4x
Premium
Premium
Financials Overview
Key metrics over the past few years+70.6%
EBITDA Margin+50.7%
Net Profit Margin+30.1%
Free Cash Flow MarginRevenue
$1.179b
+16.1%
1y CAGR+21.4%
3y CAGR+28.3%
5y CAGREarnings
$557.278m
+25.5%
1y CAGR+40.8%
3y CAGR+18.2%
5y CAGREPS
$4.37
+27.4%
1y CAGR+45.5%
3y CAGR+22.3%
5y CAGRBook Value
$332.748m
$2.054b
Assets$1.721b
Liabilities$1.509b
DebtDebt to Assets
73.5%
1.9x
Debt to EBITDAFree Cash Flow
$540.693m
+15.4%
1y CAGR+33.2%
3y CAGR+19.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company